NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Lorcaserin hydrochloride for the treatment of obesity and overweight

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes. Different measurements of obesity and overweight are needed for different ethnic populations (in particular, different BMI ranges for different ethnic groups). At the scoping workshop in March 2010, it was also noted that higher BMI ranges were needed for older populations.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The Committee will need to consider any appropriate adjustment of BMI for older people and for people of certain ethnic groups in diagnosing obesity and overweight.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Yes. The scope was amended to reflect the need for consideration of an appropriate adjustment of BMI for older people and for people of certain ethnic groups.

4. Have any additional stakeholders related to potential equality issues

Technology Appraisals: Scoping

Equality impact assessment for the Single Technology Appraisal of lorcaserin hydrochloride for the treatment of obesity and overweight Issue date: December 2012

been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified.

Approved by Associate Director (name): Helen Knight

Date: 07/12/2012